Q3 2024 Earnings Call Transcript November 10, 2024 Operator: Hello and welcome to the Relmada Therapeutics Third Quarter 2024 ...

Wells Fargo has recently raised Travere Therapeutics Inc (TVTX) stock to Overweight rating, as announced on October 21, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript November 10, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T ...

On Friday, Amicus Therapeutics, Inc. (FOLD) stock saw a modest uptick, ending the day at $10.99 which represents a slight increase of $0.01 or 0.09% from the prior close of $10.98. The stock opened at ...

Poseida Therapeutics, Inc. ( (PSTX) ) has released its Q3 earnings. Here is a breakdown of the information Poseida Therapeutics, Inc. presented ...

Pasadena Private Wealth LLC bought a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the second quarter, according to the company in its most recent filing with the ...

We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...

Good morning, and welcome to Y-mAbs Therapeutics Inc. Third Quarter Conference Call for 2024. At this time, all participants are in a listen-only mode. Instruction for the question-and-answer session ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in ...

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago. These ...